Ascendiant Capital Maintains Buy on RenovoRx, Raises Price Target to $14.5

Benzinga Newsdesk www.benzinga.com Positive 87.2%

Neg 0% Neu 0% Pos 87.2%

Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the price target from $14 to $14.5.